Methylphenidate vs Modafinil for focus
Short answer: For focus, users rate them about the same: 83% report improvement with Methylphenidate (262 reports) and 86% with Modafinil (689 reports).
Methylphenidate has 383 meta-analyses and 1,123 randomized trials on PubMed; Modafinil has 155 and 297.
Based on 567 reports about Methylphenidate and 1,613 about Modafinil. Not medical advice.
| Methylphenidate Medication | Modafinil Medication | |
|---|---|---|
| Users say it helped | 39%helped352 reports · high confidence | 50%helped936 reports · high confidence |
| Verdict | Mixed | Mixed |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 383 / 1,123 | 155 / 297 |
| Mainly used for | ||
| Focus % reporting improvement | 83% (262) | 86% (689) |
| Energy % reporting improvement | 61% (67) | 93% (485) |
| Mood % reporting improvement | 41% (66) | 64% (125) |
| Anxiety % reporting improvement | 29% (48) | 30% (87) |
| Sleep % reporting improvement | 29% (21) | 21% (94) |
| Common side effects | anxiety, jitteriness, insomnia, fatigue | insomnia, anxiety, headache, tolerance |
| Typical dose reported | Not listed | Not listed |
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“I tried both ritalin worked way better in me like way better.”
Our findings represent the most comprehensive available evidence base to inform patients, families, clinicians, guideline developers, and policymakers on the choice of ADHD medications across age groups. Taking into account both efficacy and safety, evidence from this meta-analysis supports methylphenidate in children and adolescents, and amphetamines in adults, as preferred first-choice medications for the short-term treatment of ADHD. New research should be funded urgently to assess long-term effects of these drugs.
Lancet Psychiatry, 2018 ↗“It did make me focused and alert. I was working two jobs at the time and needed every ounce of energy I could muster.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate